jy6laah

Property	Value
?:abstract	Background. Studies reporting estimates of the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have rapidly emerged. We aimed to synthesize seroprevalence data to better estimate the burden of SARS-CoV-2 infection, identify high-risk groups, and inform public health decision making. Methods. In this systematic review and meta-analysis, we searched publication databases, preprint servers, and grey literature sources for seroepidemiological study reports, from January 1, 2020 to August 28, 2020. We included studies that reported a sample size, study date, location, and seroprevalence estimate. Estimates were corrected for imperfect test accuracy with Bayesian measurement error models. We conducted meta-analysis to identify demographic differences in the prevalence of SARS-CoV-2 antibodies, and meta-regression to identify study-level factors associated with seroprevalence. We compared region-specific seroprevalence data to confirmed cumulative incidence. PROSPERO: CRD42020183634. Findings. We identified 338 seroprevalence studies including 2.3 million participants in 50 countries. Seroprevalence was low in the general population (median 3.2%, IQR 1.0-6.4%) and slightly higher in at-risk populations (median 5.4%, IQR 1.5-18.4%). Median seroprevalence varied by WHO Global Burden of Disease region (p < 0.01), from 1.0% in Southeast Asia, East Asia and Oceania to 18.8% in South Asia. National studies had lower seroprevalence estimates than local (p = 0.02) studies. Compared to White persons, Black persons (prevalence ratio [RR] 2.34, 95% CI 1.60-3.43) and Asian persons (RR 1.56, 95% CI 1.22-2.01) were more likely to be seropositive. Seroprevalence was higher among people ages 18-64 compared to 65 and over (RR 1.26, 95% CI 1.04-1.52). Health care workers had a 1.74x [95% CI: 1.18-2.58] higher risk compared to the general population. There was no difference in seroprevalence between sexes. There were 123 studies (36%) at low or moderate risk of bias. Seroprevalence estimates from national studies were median 11.9 (IQR 8.0 - 16.6) times higher than the corresponding SARS-CoV-2 cumulative incidence. Interpretation. Most of the population remains susceptible to SARS-CoV-2 infection. Public health measures must be improved to protect disproportionately affected groups, including non-White people and seniors. Measures taken in SE Asia, E Asia and Oceania, and Latin America and Caribbean may have been more effective in controlling virus transmission than measures taken in other regions. Funding. Public Health Agency of Canada through the COVID-19 Immunity Task Force.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/1jy6laah_hasAnnotation_C0962010> <https://research.tib.eu/covid-19/entity/1jy6laah_hasAnnotation_C1417168> <https://research.tib.eu/covid-19/entity/1jy6laah_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Bobrovitz%2C_N.%3B_Arora%2C_R._K.%3B_Cao%2C_C.%3B_Boucher%2C_E.%3B_Liu%2C_M.%3B_Rahim%2C_H.%3B_Donnici%2C_C.%3B_Ilincic%2C_N.%3B_Duarte%2C_N.%3B_Van_Wyk%2C_J.%3B_Yan%2C_T.%3B_Penny%2C_L.%3B_Segal%2C_M.%3B_Chen%2C_J.%3B_Whelan%2C_M.%3B_Atmaja%2C_A.%3B_Rocco%2C_S.%3B_Joseph%2C_A.%3B_Clifton%2C_D.%3B_Williamson%2C_T.%3B_Yansouni%2C_C._P.%3B_Grant%2C_T._E.%3B_Chevrier%2C_J.%3B_Papenburg%2C_J.%3B_Cheng%2C_M._P.>
?:doi	<https://research.tib.eu/covid-19/entity/10.1101/2020.11.17.20233460>
?:doi	10.1101/2020.11.17.20233460
?:license	medrxiv
?:pdf_json_files	document_parses/pdf_json/94ae2970393b4288ab7fa360787e5f01dc6ff336.json
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/94ae2970393b4288ab7fa360787e5f01dc6ff336>
?:source	MedRxiv; WHO
?:title	Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-18

Property

Value

?:abstract

Background. Studies reporting estimates of the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have rapidly emerged. We aimed to synthesize seroprevalence data to better estimate the burden of SARS-CoV-2 infection, identify high-risk groups, and inform public health decision making. Methods. In this systematic review and meta-analysis, we searched publication databases, preprint servers, and grey literature sources for seroepidemiological study reports, from January 1, 2020 to August 28, 2020. We included studies that reported a sample size, study date, location, and seroprevalence estimate. Estimates were corrected for imperfect test accuracy with Bayesian measurement error models. We conducted meta-analysis to identify demographic differences in the prevalence of SARS-CoV-2 antibodies, and meta-regression to identify study-level factors associated with seroprevalence. We compared region-specific seroprevalence data to confirmed cumulative incidence. PROSPERO: CRD42020183634. Findings. We identified 338 seroprevalence studies including 2.3 million participants in 50 countries. Seroprevalence was low in the general population (median 3.2%, IQR 1.0-6.4%) and slightly higher in at-risk populations (median 5.4%, IQR 1.5-18.4%). Median seroprevalence varied by WHO Global Burden of Disease region (p < 0.01), from 1.0% in Southeast Asia, East Asia and Oceania to 18.8% in South Asia. National studies had lower seroprevalence estimates than local (p = 0.02) studies. Compared to White persons, Black persons (prevalence ratio [RR] 2.34, 95% CI 1.60-3.43) and Asian persons (RR 1.56, 95% CI 1.22-2.01) were more likely to be seropositive. Seroprevalence was higher among people ages 18-64 compared to 65 and over (RR 1.26, 95% CI 1.04-1.52). Health care workers had a 1.74x [95% CI: 1.18-2.58] higher risk compared to the general population. There was no difference in seroprevalence between sexes. There were 123 studies (36%) at low or moderate risk of bias. Seroprevalence estimates from national studies were median 11.9 (IQR 8.0 - 16.6) times higher than the corresponding SARS-CoV-2 cumulative incidence. Interpretation. Most of the population remains susceptible to SARS-CoV-2 infection. Public health measures must be improved to protect disproportionately affected groups, including non-White people and seniors. Measures taken in SE Asia, E Asia and Oceania, and Latin America and Caribbean may have been more effective in controlling virus transmission than measures taken in other regions. Funding. Public Health Agency of Canada through the COVID-19 Immunity Task Force.

is ?:annotates of